Lenacapavir, trialed in Uganda, offers 100% protection but will it reach those who need it most? Kampala, Uganda | RONALD MUSOKE | Thanks to a landmark deal announced on July 9 by the Global Fund, Uganda is expected to be among the first countries in sub-Saharan Africa to get access to …
Read More »
Kampala, Uganda | THE INDEPENDENT | The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced that it has signed an access agreement with Pharmaceutical Company Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV prevention, for low- and middle-income countries (LMICs). This development, which …
Read More »
Kampala, Uganda | THE INDEPENDENT | USAID has been present in Uganda for over sixty years. It has funded development in agriculture, education and research in HIV/AIDS among others. USAID had a very significant impact of HIV/AID prevention and treatment efforts through PEPFAR. Specifically for HIV, at a time when …
Read More »
GENEVA, Switzerland | THE INDEPENDENT | The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The new medicine is administered by injection once every 6 months and is a significant step in improving prevention options for people at risk of HIV infection around the …
Read More »
Johannesberg, South Africa | THE INDEPENDENT | Food and Drug Administration (FDA) approval of injectable lenacapavir (LEN) for the prevention of HIV as pre-exposure prophylaxis (PrEP). LEN, developed by Gilead Sciences, is a twice-yearly injectable PrEP option that showed nearly complete protection against HIV in the landmark PURPOSE 1 and 2 …
Read More »
SPECIAL REPORT | THE INDEPENDENT | Philanthropist Bill Gates, the founder and co-chair of the Bill and Melinda Gates Foundation says more lives can be saved from HIV if modern HIV prevention tools can be spread out. The Bill and Melinda Gates Foundation has been one of the biggest funder to …
Read More »
Kampala, Uganda | THE INDEPENDENT | Activists attending the ongoing International AIDS Conference in Munich Germany have asked the manufacturer of injection Lenacapavir (LEN) which was recently proven to be safe and highly effective at preventing HIV to reduce its prices to make it affordable for all. The drug which is …
Read More »
Kampala, Uganda | THE INDEPENDENT | A new HIV prevention study has found that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected women from contracting HIV. Findings of the the PURPOSE 1 HIV prevention study among adolescent girls and young women in South Africa and Uganda was released …
Read More »
Researchers to conduct study on its efficacy on women under 25 years Kampala, Uganda | PATRICIA AKANKWATSA | Researchers of the vaccine programme at Uganda Virus Research Institute (UVRI) will start conducting a study among females below 25 years to assess the efficacy of Lenacapavir, an HIV injectable drug. Participants will …
Read More »
Kampala, Uganda | THE INDEPENDENT | Researchers will in December enroll the first participants in a clinical trial in which they are testing the effectiveness of a new HIV drug, Lenacapavir in protecting people against the virus. This study will be conducted in four districts of Mityana, Masaka, Hoima and Kalangala …
Read More »
The Independent Uganda: You get the Truth we Pay the Price
